A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC). Anlotinib combined ...
In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...
Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results